Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Law360, in “FDA Floats New Oversight Plan on Lab Tests,” by Jeff Overley. (Read the full version – subscription required.)
Following is an excerpt:
Epstein Becker Green member Bradley Merrill Thompson, who closely tracks LDT regulation, told Law360 Friday that the FDA’s discussion paper was almost certainly timed to influence the incoming administration.
“In releasing this paper now, at the beginning of the new Trump administration and the new Congress, it seems to me that FDA is putting a stake in the ground to say that the agency can be quite reasonable,” Thompson said. “This paper actually makes it hard for laboratories and others to complain to Congress that FDA is simply wanting to engage in regulatory expansion.”